Kenichiro Ishii

List of Publications by Year
in descending order

50 papers	1,375 citations	361413 20 h-index	330143 37 g-index
50 all docs	50 docs citations	50 times ranked	1736 citing authors

#	Article	IF	Citations
1	Heterogeneous induction of an invasive phenotype in prostate cancer cells by coculturing with patientâ€derived fibroblasts. Journal of Cellular Biochemistry, 2021, 122, 679-688.	2.6	5
2	Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure. Laboratory Investigation, 2020, 100, 670-681.	3.7	7
3	SOX11-induced decrease in vimentin and an increase in prostate cancer cell migration attributed to cofilin activity. Experimental and Molecular Pathology, 2020, 117, 104542.	2.1	4
4	TDP2 suppresses genomic instability induced by androgens in the epithelial cells of prostate glands. Genes To Cells, 2020, 25, 450-465.	1.2	7
5	Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications. Journal of Clinical Medicine, 2019, 8, 1716.	2.4	0
6	Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration. Journal of Clinical Medicine, 2019, 8, 1379.	2.4	4
7	Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest. Pharmacology, 2019, 103, 250-256.	2.2	23
8	Tyrosine kinase inhibitor therapy prescribed for nonâ€urologic diseases can modify PSA titers in urology patients. Prostate, 2019, 79, 259-264.	2.3	0
9	Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest. Journal of Clinical Medicine, 2019, 8, 44.	2.4	10
10	Interleukinâ€6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. Prostate, 2018, 78, 849-856.	2.3	23
11	Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 2018, 144, 89-98.	2.5	8
12	Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 472.e1-472.e9.	1.6	1
13	Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate. Journal of Clinical Medicine, 2018, 7, 68.	2.4	19
14	Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 2017, 143, 933-939.	2.5	15
15	Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer. Laboratory Investigation, 2016, 96, 338-349.	3.7	12
16	Identification of a new pharmacological activity of the phenylpiperazine derivative naftopidil: tubulin-binding drug. Journal of Chemical Biology, 2015, 8, 5-9.	2.2	14
17	Essential Roles of Epithelial Bone Morphogenetic Protein Signaling During Prostatic Development. Endocrinology, 2014, 155, 2534-2544.	2.8	13
18	Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor Î² on macrophage-differentiated cells via downregulation of prostaglandin E2. Oncology Letters, 2014, 8, 1513-1518.	1.8	2

#	Article	IF	Citations
19	Manserin as a novel histochemical neuroendocrine marker in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 787-795.	1.6	2
20	Oral Naftopidil Suppresses Human Renal-Cell Carcinoma by Inducing G1 Cell-Cycle Arrest in Tumor and Vascular Endothelial Cells. Cancer Prevention Research, 2013, 6, 1000-1006.	1.5	17
21	Activation of FGF2-FGFR Signaling in the Castrated Mouse Prostate Stimulates the Proliferation of Basal Epithelial Cells1. Biology of Reproduction, 2013, 89, 81.	2.7	12
22	Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10. Oncology Reports, 2012, 28, 2009-2015.	2.6	7
23	Low Androgen Sensitivity Is Associated With Low Levels of Akt Phosphorylation in LNCaP-E9 Cells. Journal of Andrology, 2012, 33, 660-666.	2.0	7
24	Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells. Tumor Biology, 2011, 32, 1097-1102.	1.8	15
25	Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells. Journal of Cellular Biochemistry, 2011, 112, 3604-3611.	2.6	26
26	Endocrine Disrupter Bisphenol A Increases In Situ Estrogen Production in the Mouse Urogenital Sinus. Biology of Reproduction, 2011, 84, 734-742.	2.7	78
27	Naftopidil, a Selective Î±1-Adrenoceptor Antagonist, Suppresses Human Prostate Tumor Growth by Altering Interactions between Tumor Cells and Stroma. Cancer Prevention Research, 2011, 4, 87-96.	1.5	48
28	Structural changes in Î±1-adrenoceptor antagonist-treated human prostatic stroma. Clinical and Experimental Medicine, 2010, 10, 99-106.	3.6	8
29	Effect of transforming growth factor Î± overexpression on urogenital organ development in mouse. Differentiation, 2010, 80, 82-88.	1.9	4
30	Endodermal Origin of Bladder Trigone Inferred From Mesenchymal-Epithelial Interaction. Journal of Urology, 2010, 183, 386-391.	0.4	39
31	Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo. Endocrine-Related Cancer, 2009, 16, 415-428.	3.1	24
32	Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-Î² signaling. Differentiation, 2009, 77, 95-102.	1.9	37
33	Naftopidil, a selective Î±â€1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. International Journal of Cancer, 2008, 122, 444-451.	5.1	59
34	Improvement in predicting tumorigenic phenotype of androgenâ€insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme. Cancer Science, 2008, 99, 2435-2443.	3.9	6
35	Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation. Developmental Biology, 2008, 324, 310-319.	2.0	18
36	Isolation and Characterization of LNCaP Sublines Differing in Hormone Sensitivity. Journal of Andrology, 2007, 28, 670-678.	2.0	21

#	Article	IF	Citations
37	Bisphenol A induces permanent squamous change in mouse prostatic epithelium. Differentiation, 2007, 75, 745-756.	1.9	34
38	Proprotein convertases modulate budding and branching morphogenesis of rat ventral prostate. International Journal of Developmental Biology, 2007, 51, 229-233.	0.6	7
39	Androgen-dependent prostate epithelial cell selection by targeting ARR2PBneo to the LPB-Tag model of prostate cancer. Laboratory Investigation, 2006, 86, 1074-1088.	3.7	12
40	Steroid hormones stimulate human prostate cancer progression and metastasis. International Journal of Cancer, 2006, 118, 2123-2131.	5.1	81
41	Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (Cambridge), 2005, 132, 3431-3443.	2.5	157
42	Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Laboratory Investigation, 2005, 85, 1086-1103.	3.7	22
43	Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate, 2005, 63, 369-384.	2.3	64
44	Natural history of human prostate gland: Morphometric and histopathological analysis of Japanese men. Prostate, 2005, 65, 355-364.	2.3	17
45	NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice. Cancer Research, 2004, 64, 5489-5495.	0.9	105
46	Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Letters, 2004, 207, 79-87.	7.2	59
47	Zinc and Metallothionein Levels and Expression of Zinc Transporters in Androgenâ€Independent Subline of LNCaP Cells. Journal of Andrology, 2004, 25, 154-161.	2.0	31
48	Extract from Serenoa repens Suppresses the Invasion Activity of Human Urological Cancer Cells by Inhibiting Urokinase-Type Plasminogen Activator.. Biological and Pharmaceutical Bulletin, 2001, 24, 188-190.	1.4	10
49	Inhibition of Aminopeptidase N (AP-N) and Urokinase-Type Plasminogen Activator (uPA) by Zinc Suppresses the Invasion Activity in Human Urological Cancer Cells.. Biological and Pharmaceutical Bulletin, 2001, 24, 226-230.	1.4	59
50	Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. International Journal of Cancer, 2001, 92, 49-54.	5.1	122